Patent · US Active

Hapten-carrier conjugates for treating and preventing nicotine addiction

US8026109B2 · kind B2 · utility

0Cited by

25References

3Claims

0Family size

Assignee

Nabi Biopharmaceuticals · US

Inventors

Sofiane Ennifar · Silver Spring, US
Ali Fattom · Rockville, US
Robert B. Naso · Menlo Park, US

Key dates

Filing date	Jul 14, 2010
Grant date	Sep 27, 2011
Priority date	—
Expiry date	Jul 14, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/807
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.